At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Nab-Paclitaxel, Cisplatin, and 5-FU (ACF) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
In Brief
A Phase 2 clinical trial evaluating paclitaxel albumin-stabilized nanoparticle formulation, Cisplatin, and 4 other interventions for Head and Neck Neoplasms. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This phase II trial studies the safety and effectiveness of an induction chemotherapy (ACF) consisting of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel), cisplatin and fluorouracil followed by chemoradiation therapy in treating patients with stage III-IV squamous cell cancer of the head and neck. ACF may be an effective way to reduce or downgrade locally aggressive tumors, and improve the chance of eradication by chemoradiation.
Study Details
Timeline
Interventions
ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12